750 related articles for article (PubMed ID: 36192086)
1. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
2. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy.
Si F; Liu X; Tao Y; Zhang Y; Ma F; Hsueh EC; Puram SV; Peng G
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580332
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.
Gao A; Liu X; Lin W; Wang J; Wang S; Si F; Huang L; Zhao Y; Sun Y; Peng G
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653799
[TBL] [Abstract][Full Text] [Related]
4. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
6. Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy.
Liu X; Hartman CL; Li L; Albert CJ; Si F; Gao A; Huang L; Zhao Y; Lin W; Hsueh EC; Shen L; Shao Q; Hoft DF; Ford DA; Peng G
Sci Transl Med; 2021 Mar; 13(587):. PubMed ID: 33790024
[TBL] [Abstract][Full Text] [Related]
7. TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy.
Li L; Liu X; Sanders KL; Edwards JL; Ye J; Si F; Gao A; Huang L; Hsueh EC; Ford DA; Hoft DF; Peng G
Cell Metab; 2019 Jan; 29(1):103-123.e5. PubMed ID: 30344014
[TBL] [Abstract][Full Text] [Related]
8. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment.
Zhao Y; Shao Q; Peng G
Cell Mol Immunol; 2020 Jan; 17(1):27-35. PubMed ID: 31853000
[TBL] [Abstract][Full Text] [Related]
9. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
[TBL] [Abstract][Full Text] [Related]
10. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
11. Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity.
Zheng S; Song J; Linghu D; Yang R; Liu B; Xue Z; Chen Q; Liu C; Zhong D; Hung MC; Sun L
Int J Biol Sci; 2023; 19(3):981-993. PubMed ID: 36778120
[TBL] [Abstract][Full Text] [Related]
12. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
13. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
14. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
Vilgelm AE; Johnson CA; Prasad N; Yang J; Chen SC; Ayers GD; Pawlikowski JS; Raman D; Sosman JA; Kelley M; Ecsedy JA; Shyr Y; Levy SE; Richmond A
J Natl Cancer Inst; 2016 Jun; 108(6):djv406. PubMed ID: 26719346
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
16. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
17. Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy.
Liu X; Hoft DF; Peng G
J Clin Invest; 2020 Mar; 130(3):1073-1083. PubMed ID: 32118585
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.
Noyes D; Bag A; Oseni S; Semidey-Hurtado J; Cen L; Sarnaik AA; Sondak VK; Adeegbe D
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618289
[TBL] [Abstract][Full Text] [Related]
19. PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4
Goding SR; Wilson KA; Rosinsky C; Antony PA
J Immunol; 2018 May; 200(9):3304-3311. PubMed ID: 29602773
[TBL] [Abstract][Full Text] [Related]
20. Combining precision oncology and immunotherapy by targeting the MALT1 protease.
Mempel TR; Krappmann D
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
